SEC Company Response from Coherus Oncology, Inc. (CHRS) (CIK 0001512762) (CHRS) — Jan 19, 2016
Coherus Oncology, Inc. (CHRS) (CIK 0001512762)
Date: Jan. 19, 2016 · CIK: 0001512762 · Accession: 0001193125-16-432463
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-208625
Letter
Company Acceleration Request
Coherus BioSciences, Inc.
333 Twin Dolphin Drive, Suite 600
Redwood City, CA 94065
January 19,
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention:
Michael Gershon
Suzanne Hayes
Re:
Coherus BioSciences, Inc.
Registration Statement on Form S-3 (Registration No. 333-208625)
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission (the “Commission”) of the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) of Coherus BioSciences, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on January 21, 2016, or as soon as practicable thereafter.
The Company acknowledges the following:
•
should the Commission or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Thank you for your assistance in this matter.
Very truly yours,
Coherus BioSciences, Inc.
Show Raw Text
CORRESP 1 filename1.htm Company Acceleration Request Coherus BioSciences, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City, CA 94065 January 19, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Michael Gershon Suzanne Hayes Re: Coherus BioSciences, Inc. Registration Statement on Form S-3 (Registration No. 333-208625) Ladies and Gentlemen: In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission (the “Commission”) of the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) of Coherus BioSciences, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on January 21, 2016, or as soon as practicable thereafter. The Company acknowledges the following: • should the Commission or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Thank you for your assistance in this matter. Very truly yours, Coherus BioSciences, Inc. By: /s/ Dennis M. Lanfear Dennis M. Lanfear President and Chief Executive Officer [Signature Page to Coherus BioSciences, Inc. Acceleration Letter]